OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Judith Weber, Valerie Glutsch, Eva Geissinger, et al.
British Journal of Dermatology (2019) Vol. 183, Iss. 3, pp. 559-563
Open Access | Times Cited: 24
Judith Weber, Valerie Glutsch, Eva Geissinger, et al.
British Journal of Dermatology (2019) Vol. 183, Iss. 3, pp. 559-563
Open Access | Times Cited: 24
Showing 24 citing articles:
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L. M. Reijers, Alexander M. Menzies, Alexander C.J. van Akkooi, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1178-1188
Open Access | Times Cited: 226
Irene L. M. Reijers, Alexander M. Menzies, Alexander C.J. van Akkooi, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1178-1188
Open Access | Times Cited: 226
Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients
Anthony Dixon, Αthanassios Kyrgidis, Howard K. Steinman, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 4, pp. 741-751
Closed Access | Times Cited: 10
Anthony Dixon, Αthanassios Kyrgidis, Howard K. Steinman, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 4, pp. 741-751
Closed Access | Times Cited: 10
Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy
Jian‐Guo Zhou, Bo Liang, Jianguo Liu, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 977-977
Open Access | Times Cited: 35
Jian‐Guo Zhou, Bo Liang, Jianguo Liu, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 977-977
Open Access | Times Cited: 35
Oral mucosal melanoma – A systematic review
Antoine Thuaire, Romain Nicot, M. Boileau, et al.
Journal of Stomatology Oral and Maxillofacial Surgery (2022) Vol. 123, Iss. 5, pp. e425-e432
Open Access | Times Cited: 17
Antoine Thuaire, Romain Nicot, M. Boileau, et al.
Journal of Stomatology Oral and Maxillofacial Surgery (2022) Vol. 123, Iss. 5, pp. e425-e432
Open Access | Times Cited: 17
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials
Roger Olofsson Bagge, Lars Ny, Paolo A. Ascierto, et al.
Melanoma Research (2021) Vol. 31, Iss. 2, pp. 181-185
Closed Access | Times Cited: 21
Roger Olofsson Bagge, Lars Ny, Paolo A. Ascierto, et al.
Melanoma Research (2021) Vol. 31, Iss. 2, pp. 181-185
Closed Access | Times Cited: 21
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Yana G. Najjar, Dustin McCurry, Huang Lin, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 15, pp. 4195-4204
Open Access | Times Cited: 19
Yana G. Najjar, Dustin McCurry, Huang Lin, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 15, pp. 4195-4204
Open Access | Times Cited: 19
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
Judith M. Versluis, Irene L. M. Reijers, Elisa A. Rozeman, et al.
European Journal of Cancer (2021) Vol. 148, pp. 51-57
Open Access | Times Cited: 19
Judith M. Versluis, Irene L. M. Reijers, Elisa A. Rozeman, et al.
European Journal of Cancer (2021) Vol. 148, pp. 51-57
Open Access | Times Cited: 19
In-transit metastatic cutaneous melanoma: current management and future directions
Ayushi Patel, Michael J. Carr, James Sun, et al.
Clinical & Experimental Metastasis (2021) Vol. 39, Iss. 1, pp. 201-211
Closed Access | Times Cited: 14
Ayushi Patel, Michael J. Carr, James Sun, et al.
Clinical & Experimental Metastasis (2021) Vol. 39, Iss. 1, pp. 201-211
Closed Access | Times Cited: 14
T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options
Laura Gehrcken, Tatjana Sauerer, Niels Schaft, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8679-8679
Open Access | Times Cited: 11
Laura Gehrcken, Tatjana Sauerer, Niels Schaft, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8679-8679
Open Access | Times Cited: 11
Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
Patrick Schummer, Valerie Glutsch, Lukas Haug, et al.
EJC Skin Cancer (2023) Vol. 1, pp. 100003-100003
Open Access | Times Cited: 4
Patrick Schummer, Valerie Glutsch, Lukas Haug, et al.
EJC Skin Cancer (2023) Vol. 1, pp. 100003-100003
Open Access | Times Cited: 4
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Bi‐Cheng Wang, Bo‐Ya Xiao, Pengcheng Li, et al.
Journal of Oncology (2020) Vol. 2020, pp. 1-10
Open Access | Times Cited: 11
Bi‐Cheng Wang, Bo‐Ya Xiao, Pengcheng Li, et al.
Journal of Oncology (2020) Vol. 2020, pp. 1-10
Open Access | Times Cited: 11
Therapeutic Treatment Options for In-Transit Metastases from Melanoma
Francesco Russano, Marco Rastrelli, Luigi Dall’Olmo, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3065-3065
Open Access | Times Cited: 1
Francesco Russano, Marco Rastrelli, Luigi Dall’Olmo, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3065-3065
Open Access | Times Cited: 1
The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition
Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, et al.
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, et al.
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
Bi‐Cheng Wang, Bo‐Ya Xiao, Pengcheng Li, et al.
Journal of Oncology (2021) Vol. 2021, pp. 1-1
Open Access | Times Cited: 7
Bi‐Cheng Wang, Bo‐Ya Xiao, Pengcheng Li, et al.
Journal of Oncology (2021) Vol. 2021, pp. 1-1
Open Access | Times Cited: 7
Combination of cyclophosphamide and shengbai decoction has synergistic effect against melanoma
Huimin Wang, Min Qiu, Yinghui Li, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 126, pp. 109866-109866
Open Access | Times Cited: 5
Huimin Wang, Min Qiu, Yinghui Li, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 126, pp. 109866-109866
Open Access | Times Cited: 5
Ocoxin as a complement to first line treatments in cancer
Aitor Benedicto, Eduardo Sanz, Joana Márquez
International Journal of Medical Sciences (2021) Vol. 18, Iss. 3, pp. 835-845
Open Access | Times Cited: 5
Aitor Benedicto, Eduardo Sanz, Joana Márquez
International Journal of Medical Sciences (2021) Vol. 18, Iss. 3, pp. 835-845
Open Access | Times Cited: 5
Neoadjuvante Therapie des Melanoms
Lena Fuchs, Anja Gesierich, Patrick Schummer, et al.
best practice onkologie (2024)
Closed Access
Lena Fuchs, Anja Gesierich, Patrick Schummer, et al.
best practice onkologie (2024)
Closed Access
Neoadjuvante Therapie des Melanoms
Lena Fuchs, Anja Gesierich, Patrick Schummer, et al.
Deleted Journal (2024) Vol. 30, Iss. 5, pp. 433-442
Closed Access
Lena Fuchs, Anja Gesierich, Patrick Schummer, et al.
Deleted Journal (2024) Vol. 30, Iss. 5, pp. 433-442
Closed Access
Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
Pascal Spahn, Torsten Schweiger, Andreas Buchholz, et al.
EJC Skin Cancer (2024) Vol. 2, pp. 100257-100257
Closed Access
Pascal Spahn, Torsten Schweiger, Andreas Buchholz, et al.
EJC Skin Cancer (2024) Vol. 2, pp. 100257-100257
Closed Access
Broadening indications for neoadjuvant immunotherapy
Stéphanie A. Blankenstein, Alexander C.J. van Akkooi
British Journal of Dermatology (2020) Vol. 183, Iss. 3, pp. 421-422
Closed Access | Times Cited: 1
Stéphanie A. Blankenstein, Alexander C.J. van Akkooi
British Journal of Dermatology (2020) Vol. 183, Iss. 3, pp. 421-422
Closed Access | Times Cited: 1
Data from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Yana G. Najjar, Dustin McCurry, Huang Lin, et al.
(2023)
Open Access
Yana G. Najjar, Dustin McCurry, Huang Lin, et al.
(2023)
Open Access
Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series
Ze Wang, Yapeng Wang, Shuo Wang, et al.
Annals of Medicine and Surgery (2023) Vol. 86, Iss. 1, pp. 245-251
Open Access
Ze Wang, Yapeng Wang, Shuo Wang, et al.
Annals of Medicine and Surgery (2023) Vol. 86, Iss. 1, pp. 245-251
Open Access
INHIBIDORES DE PUNTOS DE CONTROL EN EL CÁNCER DE MAMA
Brenda Gisela Martinez Oliva
Orbis Tertius - UPAL (2020) Vol. 4, Iss. 8, pp. 65-77
Open Access
Brenda Gisela Martinez Oliva
Orbis Tertius - UPAL (2020) Vol. 4, Iss. 8, pp. 65-77
Open Access
Melanome der Haut und Schleimhaut
Bastian Schilling, Anja Gesierich
Springer eBooks (2022), pp. 205-236
Closed Access
Bastian Schilling, Anja Gesierich
Springer eBooks (2022), pp. 205-236
Closed Access
